Stockscreener 앱 받기
5.955
0.76%
0.045
전일 마감가:
$5.91
열려 있는:
$5.87
하루 거래량:
16,252
Relative Volume:
0.09
시가총액:
$112.68M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.57%
1개월 성능:
+19.10%
6개월 성능:
+91.48%
1년 성능:
+0.00%
1일 변동 폭
$5.87
$6.265
1주일 범위
$5.10
$6.265
52주 변동 폭
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
400 CONNELL DRIVE, BERKELEY HEIGHTS
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
6.025 | 110.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.62 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.28 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.86 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.61 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Is Kalaris Therapeutics Inc. stock a good choice for value investorsEarnings Beat & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $11.50 Consensus Target Price from Brokerages - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully - Yahoo Finance
What analysts say about Kalaris Therapeutics Inc stockCandlestick Pattern Analysis & Rapid Capital Growth - earlytimes.in
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - The Globe and Mail
Kalaris (Nasdaq: KLRS) to present at Noble Capital 21st Emerging Growth Conference - Stock Titan
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kalaris Therapeutics, Inc. (KLRS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
What risks investors should watch in Kalaris Therapeutics Inc. stockJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Equities Analysts Offer Predictions for KLRS Q4 Earnings - Defense World
Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans - Sahm
What’s next for Kalaris Therapeutics Inc. stock priceTrade Exit Summary & Trade Opportunity Analysis - newser.com
Will Kalaris Therapeutics Inc. stock benefit from commodity pricesLong Setup & Daily Volume Surge Trade Alerts - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - newser.com
Can Kalaris Therapeutics Inc. stock deliver surprise earnings beat - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsMarket Growth Summary & Stepwise Trade Execution Plans - newser.com
Kalaris stock rating reiterated at Strong Buy by Raymond James - Investing.com Canada
Kalaris Therapeutics Reports Q3 2025 Financial Progress - MSN
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsWeekly Investment Report & Verified Momentum Watchlists - newser.com
Kalaris Therapeutics (KLRS) Price Target Increased by 10.87% to 17.34 - Nasdaq
Analyzing Kalaris Therapeutics Inc. with risk reward ratio charts2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
Applying sector rotation models to Kalaris Therapeutics Inc.Oil Prices & Technical Confirmation Trade Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysMarket Performance Summary & Consistent Profit Trading Strategies - newser.com
Does Kalaris Therapeutics Inc. qualify in momentum factor screeningMarket Rally & AI Driven Price Predictions - newser.com
William Blair Has Negative Estimate for KLRS FY2025 Earnings - Defense World
Is Kalaris Therapeutics Inc. stock positioned for digital transformationLong Setup & Expert Verified Movement Alerts - newser.com
How resilient is Kalaris Therapeutics Inc. stock in market downturnsWeekly Profit Summary & Daily Volume Surge Trade Alerts - newser.com
Will Kalaris Therapeutics Inc. outperform the marketGap Down & Fast Moving Stock Watchlists - newser.com
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.82%
1.03%
자본화:
|
볼륨(24시간):